{
    "clinical_study": {
        "@rank": "104038", 
        "arm_group": {
            "arm_group_label": "Related donors receiving plerixafor", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This is a Phase II, open-label, two strata, multicenter, prospective study of\n      plerixafor-mobilized HLA-identical sibling allografts in recipients with hematological\n      malignancies. This study will establish the safety and efficacy of subcutaneous plerixafor\n      for this purpose."
        }, 
        "brief_title": "A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor", 
        "completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "For Donors:", 
            "Related Donors Donating PBSC to a Family Member", 
            "For Recipients:", 
            "Acute Myelogenous Leukemia", 
            "Acute Lymphoblastic Leukemia", 
            "Myelodysplastic Syndrome", 
            "Chronic Myelogenous Leukemia", 
            "Non-Hodgkin's Lymphoma", 
            "Hodgkin's Disease", 
            "Chronic Lymphocytic Leukemia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hodgkin Disease", 
                "Leukemia", 
                "Leukemia, Lymphocytic, Chronic, B-Cell", 
                "Leukemia, Lymphoid", 
                "Precursor Cell Lymphoblastic Leukemia-Lymphoma", 
                "Leukemia, Myeloid, Acute", 
                "Leukemia, Myeloid", 
                "Leukemia, Myelogenous, Chronic, BCR-ABL Positive", 
                "Lymphoma", 
                "Lymphoma, Non-Hodgkin", 
                "Myelodysplastic Syndromes", 
                "Preleukemia"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Donor:\n\n          -  Donor eligibility will be determined according to applicable federal, state and local\n             regulations and institutional standards\n\n          -  18-65 years of age\n\n          -  6/6 HLA-matched sibling\n\n          -  Fulfill individual Transplant Center criteria to serve as a mobilized blood cell\n             donor\n\n          -  Serum creatinine <2.0mg/dl\n\n        Recipient:\n\n          -  18 to 65 years of age\n\n          -  6/6 HLA antigen matched sibling willing to donate PBSC for transplant\n\n          -  Fulfill individual Transplant Center Criteria for transplant\n\n          -  One of the following diagnoses:\n\n               -  Acute myelogenous leukemia (AML) in 1st remission or beyond with <5% marrow\n                  blasts and no circulating blasts.  Marrow must be done within 30 days of the\n                  start of transplant conditioning regimen in alignment with other pre-transplant\n                  assessments.\n\n               -  Acute lymphoblastic leukemia (ALL) in 1st remission or beyond with <5% marrow\n                  blasts and no circulating blasts\n\n               -  Myelodysplastic syndrome, either intermediate-1,2, or high risk by International\n                  Prognostic Scoring System or transfusion dependent\n\n               -  Chronic myelogenous leukemia (CML) failing or intolerant to tyrosine kinase\n                  inhibitor based therapy\n\n               -  Non-Hodgkin's lymphoma (NHL) or Hodgkin's disease (HD) in 2nd or greater\n                  complete remission, partial remission, or in relapse (but with at least stable\n                  disease after most recent therapy)\n\n               -  Chronic lymphocytic leukemia (CLL), relapsing after at least one prior regimen,\n                  or in remission with 17p deletion\n\n          -  Serum creatinine must be <2.0mg/dl\n\n          -  Total bilirubin and AST <3x normal\n\n          -  Infectious disease marker (IDM) monitoring will be performed per institutional\n             standards\n\n          -  Karnofsky performance status of 70% or greater.\n\n          -  Patients who have undergone a prior autologous transplantation are eligible for a\n             reduced intensity transplant only\n\n        Exclusion Criteria:\n\n        Donor:\n\n          -  Donor unwilling or unable to give informed consent, or unable to comply with the\n             protocol including required follow-up and testing\n\n          -  Donor already enrolled on another investigational agent study\n\n          -  Pregnant or breast feeding females, or females not willing or able to use adequate\n             contraception if sexually active\n\n        Recipient:\n\n          -  Patient unwilling or unable to give informed consent, or unable to comply with the\n             protocol including required follow-up and testing\n\n          -  Patients with active, uncontrolled infection at the time of the transplant\n             preparative regimen\n\n          -  Pregnant or breast feeding females, or females not willing or able to use adequate\n             contraception if sexually active\n\n          -  Patients with a history of previous CNS tumor involvement showing active symptoms or\n             signs along with documented disease on lumbar puncture and MRI of the brain within 30\n             days of start of conditioning\n\n          -  A condition, which, in the opinion of the clinical investigator, would interfere with\n             the evaluation of primary and secondary endpoints."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "64", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 24, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01696461", 
            "org_study_id": "09-PLEX"
        }, 
        "intervention": {
            "arm_group_label": "Related donors receiving plerixafor", 
            "intervention_name": "Plerixafor", 
            "intervention_type": "Drug", 
            "other_name": [
                "Mozobil", 
                "AMD3000"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": "JM 3100"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "February 4, 2014", 
        "location": [
            {
                "contact": {
                    "email": "hugo.fernandez@moffitt.org", 
                    "last_name": "Hugo Fernandez, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Tampa", 
                        "country": "United States", 
                        "state": "Florida"
                    }, 
                    "name": "H. Lee Moffitt Cancer Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "ewaller@emory.edu", 
                    "last_name": "Ned Waller, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia"
                    }, 
                    "name": "Emory University"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "aartz@medicine.bsd.uchicago.edu", 
                    "last_name": "Andrew Artz, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois"
                    }, 
                    "name": "University of Chicago"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "ychen6@partners.org", 
                    "last_name": "Yi Bin Chen, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts"
                    }, 
                    "name": "Massachusetts General Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "bmcclune@umn.edu", 
                    "last_name": "Brian McClune, DO"
                }, 
                "facility": {
                    "address": {
                        "city": "Minneapolis", 
                        "country": "United States", 
                        "state": "Minnesota"
                    }, 
                    "name": "University of Minnesota"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "litzow.mark@mayo.edu", 
                    "last_name": "Mark Litzow, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "Minnesota"
                    }, 
                    "name": "Mayo Clinic"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jdipersi@im.wustl.edu", 
                    "last_name": "John DiPersio, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "St. Louis", 
                        "country": "United States", 
                        "state": "Missouri"
                    }, 
                    "name": "Washington University"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "mitchell.horwitz@duke.edu", 
                    "last_name": "Mitch Horwitz, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Durham", 
                        "country": "United States", 
                        "state": "North Carolina"
                    }, 
                    "name": "Duke University"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "copelae@ccf.org", 
                    "last_name": "Ed Copelan, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio"
                    }, 
                    "name": "Cleveland Clinic"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "steven.devine@osumc.edu", 
                    "last_name": "Steve Devine, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio"
                    }, 
                    "name": "Ohio State University"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "craigm@wvuhealthcare.com", 
                    "last_name": "Michael Craig, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Morgantown", 
                        "country": "United States", 
                        "state": "West Virginia"
                    }, 
                    "name": "West Virginia University"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "mhamadani@mcw.edu", 
                    "last_name": "Mehdi Hamadani, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Milwaukee", 
                        "country": "United States", 
                        "state": "Wisconsin"
                    }, 
                    "name": "Medical College of Wisconsin"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients With Hematological Malignancies", 
        "overall_contact": {
            "email": "lspiess2@nmdp.org", 
            "last_name": "Laurie Spiess", 
            "phone": "612-884-8787"
        }, 
        "overall_official": {
            "affiliation": "Ohio State University", 
            "last_name": "Steve Devine, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To determine the proportion of donors whose cells can be successfully mobilized and collected with a sufficient CD34+ cell dose using plerixafor as the mobilizing agent, using an intention-to-treat analysis.   Donor mobilization following plerixafor will be considered successful if \u2265 2.0x106 CD34+ cells/kg recipient weight are collected in no more than two leukapheresis collections. All donors receiving plerixafor will be included in the analysis of the primary objective based on the intention-to-treat principle.", 
            "measure": "The proportion of donors whose cells can be successfully mobilized and collected with a sufficient CD34+ cell dose using plerixafor as the mobilizing agent, using an intention-to-treat analysis", 
            "safety_issue": "No", 
            "time_frame": "donation"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01696461"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To ascertain the incidence and severity of acute toxicities before and during apheresis experienced by donors receiving plerixafor", 
                "measure": "incidence and severity of acute toxicities before and during apheresis experienced by donors receiving plerixafor", 
                "safety_issue": "Yes", 
                "time_frame": "baseline, donation"
            }, 
            {
                "description": "To characterize the adverse effects experienced by donors receiving plerixafor up to one year post donation", 
                "measure": "Characterize the adverse effects experienced by donors receiving plerixafor up to one year post donation", 
                "safety_issue": "Yes", 
                "time_frame": "baseline, donation, 1 week, 1 month, 6 months, 1 year"
            }, 
            {
                "description": "To determine the incidence of and kinetics of neutrophil and platelet recovery after transplantation of hematopoietic cells mobilized with plerixafor", 
                "measure": "The incidence of and kinetics of neutrophil and platelet recovery after transplantation of hematopoietic cells mobilized with plerixafor", 
                "safety_issue": "Yes", 
                "time_frame": "Day 21, 28, 56, 100, 180, 270, 365"
            }, 
            {
                "description": "To describe T-cell (CD3+) and myeloid (CD33+) chimerism after transplantation of hematopoietic cells mobilized with plerixafor", 
                "measure": "Description of T-cell (CD3+) and myeloid (CD33+) chimerism after transplantation of hematopoietic cells mobilized with plerixafor", 
                "safety_issue": "No", 
                "time_frame": "Day 28, 100, 180, 365"
            }, 
            {
                "description": "To determine the incidence of primary and secondary graft failure after transplantation of hematopoietic cells mobilized with plerixafor", 
                "measure": "Incidence of primary and secondary graft failure after transplantation of hematopoietic cells mobilized with plerixafor", 
                "safety_issue": "Yes", 
                "time_frame": "Day 21, 28, 56, 100, 180, 270, 365"
            }, 
            {
                "description": "To determine the incidence of acute and chronic graft-versus host disease (GVHD) after transplantation of hematopoietic cells mobilized with plerixafor", 
                "measure": "Incidence of acute and chronic graft-versus host disease (GVHD) after transplantation of hematopoietic cells mobilized with plerixafor", 
                "safety_issue": "Yes", 
                "time_frame": "Day 21, 28, 56, 100, 180, 270, 365"
            }, 
            {
                "description": "To assess the rate and quality of immune reconstitution as evidenced by peripheral blood immunophenotype after transplantation of hematopoietic cells mobilized with plerixafor", 
                "measure": "Rate and quality of immune reconstitution as evidenced by peripheral blood immunophenotype after transplantation of hematopoietic cells mobilized with plerixafor", 
                "safety_issue": "Yes", 
                "time_frame": "Day 28, 100, 180, 365"
            }, 
            {
                "description": "To determine the incidence of CMV reactivation after transplantation of hematopoietic cells mobilized with plerixafor in CMV seropositive recipients", 
                "measure": "incidence of CMV reactivation after transplantation of hematopoietic cells mobilized with plerixafor in CMV seropositive recipients", 
                "safety_issue": "Yes", 
                "time_frame": "Day 100, 180, 365"
            }, 
            {
                "description": "To determine the incidence of treatment-related mortality and disease relapse/progression after transplantation of hematopoietic cells mobilized with plerixafor", 
                "measure": "incidence of treatment-related mortality and disease relapse/progression after transplantation of hematopoietic cells mobilized with plerixafor", 
                "safety_issue": "Yes", 
                "time_frame": "Day 21, 28, 56, 100, 180, 270, 365"
            }, 
            {
                "description": "To determine the probability of progression-free and overall survival after transplantation of hematopoietic cells mobilized with plerixafor", 
                "measure": "probability of progression-free and overall survival after transplantation of hematopoietic cells mobilized with plerixafor", 
                "safety_issue": "Yes", 
                "time_frame": "Day 21, 28, 56, 100, 180, 270, 365"
            }, 
            {
                "description": "To describe the cellular composition of allografts mobilized with plerixafor (stem/progenitor cells, T/B/NK-cells)", 
                "measure": "describe the cellular composition of allografts mobilized with plerixafor (stem/progenitor cells, T/B/NK-cells)", 
                "safety_issue": "No", 
                "time_frame": "donation"
            }
        ], 
        "source": "Center for International Blood and Marrow Transplant Research", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Genzyme, a Sanofi Company", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Sanofi", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "Center for International Blood and Marrow Transplant Research", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}